NCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
Ohio State University Comprehensive Cancer Center
Five Prime Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center